Shield Therapeutics Gestion
Gestion contrôle des critères 2/4
Le PDG Shield Therapeutics est Karl Lundstrom, nommé en Jul2024, a un mandat de 5.17 ans. La rémunération annuelle totale est $ 590.00K, composée du salaire de 81% et des bonus 19%, y compris les actions et options de la société. détient directement 0.055% des actions de la société, d'une valeur de £ 36.56K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 6 ans et 5.6 ans.
Informations clés
Karl Lundstrom
Directeur général
US$590.0k
Rémunération totale
| Pourcentage du salaire du PDG | 81.02% |
| Durée du mandat du directeur général | 2yrs |
| Propriété du PDG | 0.05% |
| Durée moyenne d'occupation des postes de direction | 6yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 5.6yrs |
Mises à jour récentes de la gestion
Recent updates
Mise à jour du récit • Jul 07
STX: Japan Trial Progress Will Drive Future Earnings Upside
Analysts have reduced their fair value estimate for Shield Therapeutics from £0.14 to £0.12, reflecting updated assumptions around revenue growth, profit margins, and a higher expected future P/E multiple. What’s in the News for Shield Therapeutics Shield Therapeutics reported that partner MEDLEAP Pharma, a subsidiary of Vital KSK Holdings Inc., enrolled the first patient in a Phase II clinical trial in Japan for ACCRUFeR (ferric maltol) as a potential treatment for Pulmonary Arterial Hypertension, following confirmation of the development plan by Japan’s Pharmaceuticals and Medical Devices Agency, source: company announcement.
Mise à jour du récit • Jun 23
STX: Pediatric And Pulmonary Hypertension Trials Will Support Future Upside
Analysts have trimmed their fair value estimate for Shield Therapeutics from £0.17 to £0.17 after updating their assumptions for revenue growth, profit margins and the future P/E multiple, resulting in a slightly lower price target. What's in the News for Shield Therapeutics Shield Therapeutics announced that partner MEDLEAP Pharma, a subsidiary of Vital KSK Holdings, has enrolled the first patient in a Phase II clinical trial in Japan evaluating ACCRUFeR (ferric maltol) for Pulmonary Arterial Hypertension, following prior confirmation of the development plan by Japan's Pharmaceuticals and Medical Devices Agency.Mise à jour du récit • Jun 05
STX: Pediatric And Japan Trial Milestones Will Drive Future Earnings Upside
Shield Therapeutics' analyst price target is now set at £0.14. Analysts attribute this level to unchanged fair value, discount rate and P/E assumptions, combined with modest adjustments to revenue growth and profit margin forecasts.Mise à jour du récit • May 21
STX: Pediatric And Asia Regulatory Milestones Will Drive Future Earnings Upside
Shield Therapeutics’ latest analyst price target has been set at £0.14, with analysts attributing this unchanged fair value to a slightly adjusted discount rate, modestly revised revenue growth and profit margin assumptions, and a recalibrated future P/E multiple. What's in the News MEDLEAP Pharma, a subsidiary of Vital KSK Holdings Inc., enrolled the first patient in a Phase II exploratory clinical trial in Japan evaluating ACCRUFeR (ferric maltol) for Pulmonary Arterial Hypertension.Mise à jour du récit • May 04
STX: Pediatric And Asia Expansion Will Drive Future Earnings Upside
Analysts have adjusted their price target on Shield Therapeutics to £0.14 per share, with the change linked to updated assumptions that maintain the fair value level while recalibrating revenue growth, profit margin and future P/E expectations. What's in the News Partner MEDLEAP Pharma enrolled the first patient in a Phase II clinical trial in Japan testing ACCRUFeR (ferric maltol) as a potential treatment for pulmonary arterial hypertension, following prior confirmation of the development plan by Japan's Pharmaceuticals and Medical Devices Agency (Product-Related Announcement).Mise à jour du récit • Apr 18
STX: Expanded Pediatric Reach And China Entry Will Support Stronger Future Earnings
Analysts have trimmed their fair value estimate for Shield Therapeutics to £0.14 per share, citing updated assumptions that combine a lower revenue growth outlook with a higher projected profit margin and a reduced future P/E multiple. What's in the News EMA's Committee for Medicinal Products for Human Use issued a positive opinion to extend FeRACCRU's indication to include adolescents, so it is now indicated for iron deficiency in adults and pediatric patients 12 years and older in Europe, with all measures in the agreed Pediatric Investigation Plan confirmed as fulfilled (Key Developments).Article d’analyse • Apr 12
Shield Therapeutics plc (LON:STX) Released Earnings Last Week And Analysts Lifted Their Price Target To UK£0.17
It's been a good week for Shield Therapeutics plc ( LON:STX ) shareholders, because the company has just released its...Mise à jour du récit • Apr 03
STX: Pediatric And China Approvals Will Expand Future Earnings Power
Analysts have maintained their fair value estimate for Shield Therapeutics at £0.14. The discount rate remains unchanged, and updated assumptions for revenue growth, profit margin and future P/E support the latest price target view.Mise à jour du récit • Mar 20
STX: Pediatric Label Expansion And Added Exclusivity Will Support Future Upside
Analysts have kept their fair value framework for Shield Therapeutics broadly unchanged, with a slightly adjusted profit margin outlook and future P/E assumption. These updates feed into a refreshed price target in £ terms that remains closely aligned with the prior figure.Mise à jour du récit • Mar 06
STX: Pediatric Expansion And China Filing Will Redefine Earnings Power
Analysts have lifted their price target for Shield Therapeutics to £0.14 from £0.10, citing updated assumptions for fair value, discount rate, revenue, profit margin and future P/E that they view as better aligned with the company’s current outlook. What's in the News Shield Therapeutics filed and received acceptance of a Marketing Authorisation Application for ACCRUFeR with China’s National Medical Products Administration for adults with iron deficiency, supported by prior US FDA data and a Phase 3 study in Chinese adults with iron deficiency anemia and inflammatory bowel disease who are intolerant to oral ferrous products (Key Developments).Mise à jour du récit • Feb 19
STX: Pediatric Expansion And Extended Exclusivity Will Support Future Upside Potential
Analysts have kept their fair value estimate for Shield Therapeutics broadly steady at £0.17 per share, reflecting only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that they see as refinements rather than a change in thesis. What's in the News The FDA approved an extension of the indication for ACCRUFeR (ferric maltol) to treat iron deficiency in adult and pediatric patients 10 years and older, following a priority review supported by a Phase 3 pediatric trial in children from 1 month of age with iron deficiency anemia (Key Developments).Mise à jour du récit • Feb 05
STX: Expanded Pediatric Indications And New Market Approvals Will Drive Upside
Analysts have nudged their price target for Shield Therapeutics slightly higher, reflecting small adjustments to revenue growth, profit margin expectations, and the implied future P/E multiple. What's in the News Shield Therapeutics issued earnings guidance for 2026, indicating that it expects to deliver an operating profit in that year (company guidance).Mise à jour du récit • Jan 22
STX: Pediatric Expansion And New Market Approvals Will Support Future Upside
Analysts have lifted their price target on Shield Therapeutics from £0.16 to about £0.17, citing updated assumptions for revenue growth, profit margins, and a slightly lower future P/E multiple. What’s in the News US FDA grants priority review approval to extend ACCRUFeR’s indication to adolescents, covering iron deficiency treatment in patients 10 years and older, backed by positive Phase 3 pediatric trial data (FORTIS/ST10-01-305) (Key Developments).Mise à jour du récit • Jan 07
STX: Expanded Pediatric And Global Approvals Will Support Future Upside
Analysts have trimmed their price target on Shield Therapeutics slightly, citing updated expectations for revenue growth of about 41.81%, a lower projected profit margin of around 13.33% and a higher future P/E of roughly 17.49x. Together, these factors imply less upside potential from current levels in cash terms than previously estimated.Mise à jour du récit • Dec 18
STX: Future US Label Expansion Could Still Leave Shares Vulnerable
Analysts have raised their price target for Shield Therapeutics from 0.03 dollars to 0.10 dollars, citing slightly stronger long term revenue growth expectations, while applying a higher discount rate and more conservative profit margin and valuation multiples. What's in the News Presentation of pediatric FORTIS PK sub study at the American Society of Hematology conference in December 2025 showed ferric maltol is well absorbed across pediatric age groups, with maltol rapidly metabolized and excreted, supporting its suitability for iron replacement in children and adolescents (company announcement).Mise à jour du récit • Dec 04
STX: New Regulatory Approvals And Pediatric Data Will Drive Future Upside
Analysts have modestly increased their price target on Shield Therapeutics, citing slightly stronger projected revenue growth, a marginally lower profit margin, and a modestly higher future price-to-earnings multiple. What's in the News The Korean Ministry of Food and Drug Safety granted regulatory approval for ACCRUFeR (ferric maltol) in adults with iron deficiency, opening a new commercial market and triggering eligibility for milestones and royalties (company announcement).Article d’analyse • Nov 25
Shield Therapeutics plc's (LON:STX) Subdued P/S Might Signal An Opportunity
With a median price-to-sales (or "P/S") ratio of close to 2.6x in the Pharmaceuticals industry in the United Kingdom...Mise à jour du récit • Nov 20
STX: FDA Priority Review and Regulatory Approvals Will Drive Significant Upside
Analysts have modestly raised their price target for Shield Therapeutics from $0.16 to $0.16 per share. This change reflects updated assumptions around discount rates and profit margins, while maintaining a cautiously optimistic outlook.Mise à jour du récit • Nov 06
STX: Upcoming FDA Decision Will Drive Confidence After Positive Pediatric Results
Analysts have maintained their price target for Shield Therapeutics at $0.16, citing stable projections in key financial metrics, including revenue growth and profit margin improvements, as justification for the unchanged valuation. What's in the News Positive efficacy, tolerability, and palatability results for the ferric maltol pediatric FORTIS clinical trial were presented at the American Association of Pediatrics National Conference.Mise à jour du récit • Oct 22
Analysts Maintain Target for Shield Therapeutics Amid Positive Clinical News and Stable Valuation Metrics
Narrative Update on Shield Therapeutics: Analyst Price Target Revision Analysts have maintained their price target for Shield Therapeutics at £0.16. This reflects confidence in the company's prospects, given stable fair value estimates and consistent growth expectations.Mise à jour du récit • Oct 08
Global Aging Trends And Early Detection Will Unlock Markets
Analysts have raised their price target on Shield Therapeutics from $0.14 to $0.16 per share, citing improved profit margin expectations and a steady long-term outlook, despite minor adjustments to growth forecasts. What's in the News Positive efficacy, tolerability, and palatability results for ferric maltol pediatric FORTIS clinical trial were presented at the AAP National Conference, showing significant hemoglobin improvements with no serious adverse events reported (Key Developments).Article d’analyse • Aug 23
The Market Lifts Shield Therapeutics plc (LON:STX) Shares 76% But It Can Do More
Despite an already strong run, Shield Therapeutics plc ( LON:STX ) shares have been powering on, with a gain of 76% in...Nouveau récit • Aug 03
Global Aging Trends And Early Detection Will Unlock Markets
An expanding addressable market and greater screening activity are driving strong prescription growth and recurring revenues for Shield's main product.Article d’analyse • Jun 28
Shield Therapeutics plc (LON:STX) Soars 27% But It's A Story Of Risk Vs Reward
Shield Therapeutics plc ( LON:STX ) shares have had a really impressive month, gaining 27% after a shaky period...Article d’analyse • Feb 06
Even With A 26% Surge, Cautious Investors Are Not Rewarding Shield Therapeutics plc's (LON:STX) Performance Completely
Shield Therapeutics plc ( LON:STX ) shareholders have had their patience rewarded with a 26% share price jump in the...Article d’analyse • Oct 30
Shield Therapeutics plc (LON:STX) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny
The Shield Therapeutics plc ( LON:STX ) share price has softened a substantial 28% over the previous 30 days, handing...Article d’analyse • Oct 12
Shield Therapeutics (LON:STX) Is Making Moderate Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d’analyse • Aug 01
Shield Therapeutics plc's (LON:STX) Shares Leap 44% Yet They're Still Not Telling The Full Story
Despite an already strong run, Shield Therapeutics plc ( LON:STX ) shares have been powering on, with a gain of 44% in...Article d’analyse • Jun 13
Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now
Key Insights Shield Therapeutics will host its Annual General Meeting on 20th of June CEO Greg Madison's total...Article d’analyse • May 22
Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost
Shield Therapeutics plc ( LON:STX ) shareholders are no doubt pleased to see that the share price has bounced 35% in...Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Dec 31 2025 | US$590k | US$478k | -US$18m |
| Sep 30 2025 | n/a | n/a | -US$19m |
| Jun 30 2025 | n/a | n/a | -US$21m |
| Mar 31 2025 | n/a | n/a | -US$24m |
| Dec 31 2024 | US$154k | n/a | -US$27m |
| Sep 30 2024 | n/a | n/a | -US$32m |
| Jun 30 2024 | n/a | n/a | -US$36m |
| Mar 31 2024 | n/a | n/a | -US$35m |
| Dec 31 2023 | US$42k | n/a | -US$33m |
| Sep 30 2023 | n/a | n/a | -US$40m |
| Jun 30 2023 | n/a | n/a | -US$47m |
| Mar 31 2023 | n/a | n/a | -US$49m |
| Dec 31 2022 | US$63k | n/a | -US$50m |
| Sep 30 2022 | n/a | n/a | -US$39m |
| Jun 30 2022 | n/a | n/a | -US$30m |
| Mar 31 2022 | n/a | n/a | -US$29m |
| Dec 31 2021 | US$41k | n/a | -US$27m |
Rémunération vs marché: La rémunération totale de Karl ($USD 590.00K ) est supérieure à la moyenne des entreprises de taille similaire sur le marché UK ($USD 411.87K ).
Rémunération et revenus: La rémunération de Karl a augmenté alors que l'entreprise n'est pas rentable.
PDG
Karl Lundstrom (64 yo)
2yrs
Titularisation
US$590,000
Compensation
Mr. Karl Anders Lundstrom is Director of Cinclus Pharma Holding AB (publ) from May 21, 2026. Mr. Lundstrom serves as Chief Executive Officer at Shield Therapeutics plc since February 1, 2025 and serves as...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO, Interim CFO & Director | 2yrs | US$590.00k | 0.055% £ 36.6k | |
| Co-Founder & Non Executive Director | 18.5yrs | US$129.00k | 1.09% £ 728.2k | |
| General Counsel | 8.8yrs | pas de données | pas de données | |
| Senior VP of Manufacturing & Strategic Alliances | no data | pas de données | pas de données | |
| Head of Pharmacovigilance & Medical Information | no data | pas de données | pas de données | |
| Chief Commercial Officer | 3.3yrs | pas de données | pas de données |
6.0yrs
Durée moyenne de l'emploi
60yo
Âge moyen
Gestion expérimentée: L'équipe dirigeante de STX est chevronnée et expérimentée (6 années d'ancienneté moyenne).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO, Interim CFO & Director | 5.2yrs | US$590.00k | 0.055% £ 36.6k | |
| Co-Founder & Non Executive Director | 6.1yrs | US$129.00k | 1.09% £ 728.2k | |
| Independent Non Executive Chairman | 8yrs | US$132.00k | 0.51% £ 343.8k | |
| Non-Executive Director | 2yrs | US$53.00k | pas de données | |
| Independent Vice Chairman | 10.4yrs | US$64.00k | 0.017% £ 11.1k | |
| Notable Scientific Advisory Board | no data | pas de données | pas de données | |
| Independent Non-Executive Director | 5.2yrs | US$53.00k | 0.025% £ 17.0k | |
| Notable Scientific Advisory Board | no data | pas de données | pas de données | |
| Notable Scientific Advisory Board | no data | pas de données | pas de données | |
| Notable Scientific Advisory Board | no data | pas de données | pas de données |
5.6yrs
Durée moyenne de l'emploi
64yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de STX sont considérés comme expérimentés (ancienneté moyenne 5.6 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/13 05:06 |
| Cours de l'action en fin de journée | 2026/07/13 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Shield Therapeutics plc est couverte par 10 analystes. 3 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Howard Miller | Canaccord Genuity |
| Mark Brewer | Cavendish |
| Michael Mitchell | Cavendish |